MARIMED INC
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page | ||
|---|---|---|
| Part I | ||
| Item 1 | Business | 2 |
| Item 1A | Risk Factors | 7 |
| Item 1B | Unresolved Staff Comments | 18 |
| Item 1C | Cybersecurity | 18 |
| Item 2 | Properties | 19 |
| Item 3 | Legal Proceedings | 20 |
| Item 4 | Mine Safety Disclosures | 21 |
| Part II | ||
| Item 5 | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 22 |
| Item 6 | Reserved | 22 |
| Item 7 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 22 |
| Item 7A | Quantitative and Qualitative Disclosures About Market Risk | 32 |
| Item 8 | Financial Statements and Supplementary Data | 33 |
| Item 9 | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 73 |
| Item 9A | Controls and Procedures | 73 |
| Item 9B | Other Information | 74 |
| Item 9C | Disclosure Regarding Foreign Jurisdictions that Prevent Inspection | 74 |
| Part III | ||
| Item 10 | Directors, Executive Officers and Corporate Governance | 75 |
| Item 11 | Executive Compensation | 75 |
| Item 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 75 |
| Item 13 | Certain Relationships and Related Transactions, and Director Independence | 75 |
| Item 14 | Principal Accountant Fees and Services | 75 |
| Part IV | ||
| Item 15 | Exhibits and Financial Statement Schedules | 76 |
| Signatures | 81 | |
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING INFORMATION
This Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended. These statements involve risks and uncertainties, and our actual results could differ significantly from those discussed herein. These include statements about our expectations, beliefs, intentions or strategies for the future, which the Company indicates by words or phrases such as “anticipate,” “expect,” “estimate,” “could,” “should,” “would,” “project,” “predict,” “intend,” “plan,” “will,” “believe,” and similar language, including those set forth in the discussion under “Description of Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as those discussed elsewhere in this Annual Report on Form 10-K. The Company bases its forward-looking statements on information currently available to it, and the Company believes that the assumption and expectations reflected in such forward-looking statements are reasonable. The Company assumes no obligation to revise or update any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Statements contained in this Form 10-K that are not historical facts are forward-looking statements that are subject to the “safe harbor” created by the Private Securities Litigation Reform Act of 1995.
Unless expressly indicated or the context requires otherwise, the terms "MariMed", "company", "we", "us", "our", and "Company" in this document refer to MariMed Inc., a Delaware corporation, and, where appropriate, its subsidiaries.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.